In cardiovascular outcomes trials, GLP-1 receptor agonists reduced albuminuria and slowed eGFR decline, even when used with other potentially protective therapies in populations with T2D or obesity and relatively low CKD risk
Additional treatment options for this group are really needed. Novo Nordisks CEO told CNN in August that the company had heard many similar anecdotal reports
Glycine does not accelerate or delay semaglutide onset of action
The different maximums reflect different molecular potencies and different receptor mechanisms
It can be prescribed to: Adults and pediatric patients aged 12 years and older with obesity Adults with overweight and a weight-related health condition, such as high cholesterol, high blood pressure, type 2 diabetes, or sleep apnea Adults who have heart disease and either obesity or overweight Some people should avoid taking Wegovy
One of the most common side effects of GLP-1 drugs is gastrointestinal discomfort, including nausea, vomiting, and constipation
